AMPE - Ampio highlights integrated data from Ampion osteoarthritis of the knee trials

Ampio Pharmaceuticals ([[AMPE]] +1.4%) posts newly integrated data from four of its earlier clinical trials utilizing the company's Ampion treatment for treating osteoarthritis of the knee ((OAK)).The pooled data showed a reduction in pain of 34.3% at two weeks (compared to 28.6% for saline, p value 0.041), 38.1% at ten weeks (30.4% for saline, p value 0.006) and 36% at twelve weeks (25.7% for saline, p value <0.001).No drug-related serious adverse events ((SAEs)) or treatment-related deaths have occurred, and the majority of adverse events ((AEs)) were unrelated to treatment.The company had revealed positive results from its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress due to COVID-19, in April.

For further details see:

Ampio highlights integrated data from Ampion osteoarthritis of the knee trials